[Definition and standardization of histocompatibility requests depending on patient course and donor type: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC) and the Francophone Society of Histocompatibility and Immunogenetics (SFHI)].

Définition et standardisation des bilans d’histocompatibilité en fonction du parcours du patient et du type de donneur : recommandations de la Société francophone de greffe de moelle et de thérapie cellulaire (SFGM-TC) et de la Société Francophone d’Histocompatibilité et Immunogénétique (SFHI).

Journal

Bulletin du cancer
ISSN: 1769-6917
Titre abrégé: Bull Cancer
Pays: France
ID NLM: 0072416

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 07 01 2021
revised: 27 01 2021
accepted: 27 01 2021
pubmed: 11 5 2021
medline: 5 1 2022
entrez: 10 5 2021
Statut: ppublish

Résumé

Standardization of histocompatibility tests for allogeneic hematopoietic cell transplants, harmonization of information transmitted to clinicians are part of quality improvement and optimization of human and economic resources. New HLA typing technologies provide high-resolution information within a reasonable time frame. Knowledge of high-resolution HLA typing for the patient and their relatives is essential for a better interpretation of compatibilities. HLA-DPB1 typing must be considered in transplant field regardless of the donor type. The benefits of using search and match programs are considerable. It saves time and reduces additional typing costs by providing rapid information about the likelihood to identify a matched unrelated donor. A backup therapy considering alternative cell sources or treatment can therefore be quickly implemented. The importance of knowledge and consideration of patient immunization for donor choice was explored in previous workshops of the SFGM-TC (2018 and 2019). The published recommendations remain applicable. The routine follow-up protocol and in case of desensitization will be detailed here. This harmonization must be accompanied by the standardization of information to be returned to the clinician regarding the donor finding possibilities for the patient. This will guarantee a similar quality level in every center.

Identifiants

pubmed: 33966883
pii: S0007-4551(21)00136-3
doi: 10.1016/j.bulcan.2021.01.024
pii:
doi:

Substances chimiques

HLA-DP beta-Chains 0
HLA-DPB1 antigen 0

Types de publication

Journal Article Practice Guideline Review

Langues

fre

Sous-ensembles de citation

IM

Pagination

S45-S52

Informations de copyright

Copyright © 2021 Société Française du Cancer. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Valérie Dubois (V)

Établissement Français du Sang, laboratoire Histocompatibilité, 69150 Décines, France. Electronic address: valerie.dubois@efs.sante.fr.

Kahina Amokrane (K)

Hôpital Saint Louis, laboratoire d'Immunologie Histocompatibilité, 75010 Paris, France.

Roberto Crocchiolo (R)

Servizio di Immunoematologia e Medicina Trasfusionale, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italie.

Marylise Fort (M)

CHU de Toulouse, laboratoire d'Histocompatibilité, Hôpital de RANGUEIL, 31059 Toulouse, France.

Nicolas Guillaume (N)

CHU Amiens, laboratoire d'Histocompatibilité, 80054 Amiens, France.

Anne Kennel (A)

Établissement Français du Sang, laboratoire Histocompatibilité, 42000 Saint-Étienne, France.

Sandra Michiels (S)

Institut Jules Bordet, Département d'Hématologie, Université Libre de Bruxelles, 1000 Bruxelles, Belgique.

Mamy Ralazamahaleo (M)

CHU de Bordeaux, laboratoire d'Immunologie-Immunogénétique, 33076 Bordeaux.

Paul-Olivier Rouzaire (PO)

CHU de Clermont-Ferrand, Service d'Histocompatibilité et d'Immunogénétique, Université Clermont Auvergne, EA 7453 CHELTER, 63003 Clermont-Ferrand.

Ibrahim Yakoub-Agha (I)

CHU de Lille, Univ Lille, Inserm U1286, Infinite, 59000 Lille, France.

Catherine Faucher (C)

Direction prélèvements et greffes de CSH, Direction médicale et scientifique, Agence de la biomédecine, 93212 St-Denis, La Plaine.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH